Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis

Arch Dermatol. 2012 Dec;148(12):1423-5. doi: 10.1001/2013.jamadermatol.80.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Acute Disease
  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Male
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Retrospective Studies
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept